The long-term risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: a cohort study
- PMID: 22288441
- DOI: 10.1111/j.1365-2036.2012.04998.x
The long-term risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: a cohort study
Abstract
Background: People with coeliac disease are known to be at increased risk of malignancy; however, long-term risks of malignancy beyond 10-15 years are largely unstudied.
Aim: To estimate how long an increased risk of malignancy among coeliac disease patients persists following diagnosis and treatment, using data from a cohort with an average follow-up of 25 years.
Methods: People with coeliac disease diagnosed in the Lothian region of Scotland, United Kingdom, were followed up from January 1970 or the date of coeliac disease diagnosis (whichever was later) until the first occurrence of death, emigration, cancer diagnosis or the end of 2004. Standardised incidence ratios were calculated to compare the cancer incidence rates among this group with those from the population of Scotland.
Results: Overall, the risk of any malignancy in coeliac disease patients compared with the general population was increased 40% [standardised incidence ratio (SIR) = 1.41; 95% CI 1.09-1.78]. An increased risk for cancer overall persisted for up to 15 years, beyond which no overall increase in malignancy risk was observed, although the risk of non-Hodgkin's lymphoma remained raised beyond 15 years (SIR = 5.15; 95% CI 1.40-13.2). In total, there were 14 non-Hodgkin's lymphomas in the cohort, providing an overall incidence of 1.3 per 1000 person-years.
Conclusions: The overall risk of malignancy in coeliac patients declines with time after diagnosis and is not significantly increased after 15 years. Most of the increased risk can be attributed to the development of haematological malignancies, despite their very low absolute rate of occurrence.
© 2012 Blackwell Publishing Ltd.
Similar articles
-
Malignancies and mortality in patients with coeliac disease and dermatitis herpetiformis: 30-year population-based study.Dig Liver Dis. 2006 Jun;38(6):374-80. doi: 10.1016/j.dld.2006.03.002. Epub 2006 Apr 14. Dig Liver Dis. 2006. PMID: 16627018
-
Risk of malignancy in diagnosed coeliac disease: a 24-year prospective, population-based, cohort study.Aliment Pharmacol Ther. 2004 Oct 1;20(7):769-75. doi: 10.1111/j.1365-2036.2004.02177.x. Aliment Pharmacol Ther. 2004. PMID: 15379837
-
Malignancy and survival in dermatitis herpetiformis: a comparison with coeliac disease.Gut. 1996 Apr;38(4):528-30. doi: 10.1136/gut.38.4.528. Gut. 1996. PMID: 8707082 Free PMC article.
-
[Cancer risk in coeliac disease].Tidsskr Nor Laegeforen. 2008 Oct 23;128(20):2312-5. Tidsskr Nor Laegeforen. 2008. PMID: 19096486 Review. Norwegian.
-
[Guideline 'Coeliac disease and dermatitis herpetiformis'].Ned Tijdschr Geneeskd. 2010;154:A1904. Ned Tijdschr Geneeskd. 2010. PMID: 21029498 Review. Dutch.
Cited by
-
Risk of lymphoproliferative malignancy in celiac patients with a family history of lymphoproliferative malignancy.J Gastroenterol. 2013 Dec;48(12):1324-31. doi: 10.1007/s00535-013-0757-6. Epub 2013 Feb 27. J Gastroenterol. 2013. PMID: 23440554 Free PMC article.
-
Prevalence of malignant neoplasms in celiac disease patients - a nationwide United States population-based study.World J Clin Oncol. 2024 Aug 24;15(8):1048-1060. doi: 10.5306/wjco.v15.i8.1048. World J Clin Oncol. 2024. PMID: 39193153 Free PMC article.
-
Adjuvants and lymphoma risk as part of the ASIA spectrum.Immunol Res. 2015 Feb;61(1-2):79-89. doi: 10.1007/s12026-014-8622-0. Immunol Res. 2015. PMID: 25582758 Review.
-
Review article: Systemic consequences of coeliac disease.Aliment Pharmacol Ther. 2022 Jul;56 Suppl 1(Suppl 1):S64-S72. doi: 10.1111/apt.16912. Aliment Pharmacol Ther. 2022. PMID: 35815828 Free PMC article. Review.
-
The Long-Term Safety and Quality of Life Effects of Oats in Dermatitis Herpetiformis.Nutrients. 2020 Apr 11;12(4):1060. doi: 10.3390/nu12041060. Nutrients. 2020. PMID: 32290504 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical